Christopher Graham

Assistant Professor of @UMNHOT @UMNCancer. Former BMT Fellow @MayoClinic. Thoughts are my own.

[Christopher Graham @ChrisGrahamMD]

Azer-cel shows promising results in CAR-naive NHLs and CAR-exposed DLBCL, but will this allo-CAR overcome and become the first commercially available allogeneic CAR-T?. Stay tuned. #ASCO2026

[Supriya Gupta, MD @SupriyaGuptaMD]

#ASCO26 attendees: Join me today at 1:30 pm at E450a as we discuss our results of the phase 1b study using Azer-cel, an allogeneic CD19 CAR-T in R/R NHL and CLL, not previously exposed to CAR-T.

@TeamImugene @UMNCancer @UMNews #lymsm

[GvHD Hub @gvhd_hub]

CONGRESS | #ASH25 | PRESENTATION

Samer Srour presents preliminary data of a phase I trial evaluating Orca-Q with (n = 18) or without (n = 26) GvHD prophylaxis (tacrolimus) in patients receiving allo-HSCT with 8/8 HLA-matched donors. Removal of pharmacologic GvHD prophylaxis did not increase GvHD rates and may improve infection rates. At 12 months, cumulative incidence of Grade ≥3 #aGvHD was 8.4% in the prophylaxis cohort vs 5.6% in the without prophylaxis cohort; similarly, incidence of moderate–severe #cGvHD was 11.8% and 0%, respectively.

Follow our live feed for more updates: https://t.co/oAmzxmLxXa

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress
@MDAndersonNews

[Christopher Graham @ChrisGrahamMD]

ICYMI: See our article in today’s ASH News Daily highlighting Dr. Nancy Speck’s E Donnall Thomas Lecture and Prize on her groundbreaking research in CBF leukemia @ASH_hematology @JoselleCookMD #ASH25 @SupriyaGuptaMD
https://t.co/ZmJi0O2aWo

[Christopher Graham @ChrisGrahamMD]

#ASHkudos to Dr. Sanni, one of our fellows at #UMN who presented his research on HgSC disease cardiopulmonary risks and outcomes in inpatient setting. #ASH25

[Abdulsabur Sanni(Abdul) @Dr_AbdulMD]

The first time I came to ash in 2023, I always admired the people giving oral presentations. I also wondered if I would ever be one of them. Today that dream came true ❤️ #ASH2025

[Malvika Gupta @MalvikaGuptaMD]

Excited to share our abstract on cardiotoxicities with CAR-T therapy at #ASH25
Stop by poster #6301 to say hi 👋

@ChrisGrahamMD @SupriyaGuptaMD

[Christopher Graham @ChrisGrahamMD]

#ASHkudos to all my ASH News Daily co-writers. It had been a pleasure writing with all of you. #ASH25 @JoselleCookMD @majorajay @SupriyaGuptaMD @ZanwarSaurabh @EmperorBlackMD @CKBrierley @ASH_hematology

[Charlotte Brierley @CKBrierley]

It’s been a lot of fun acting as @JoselleCookMD's deputy in bringing #ASH25 ASHNewsDaily to life! Great to finally meet the team IRL today 😍
@ZanwarSaurabh
@EmperorBlackMD
@majorajay
@ChrisGrahamMD
@supriyaguptaMD
@ASH_hematology

[Christopher Graham @ChrisGrahamMD]

#ASHkudos to Dr. Nancy Speck, the E. Donnall Thomas Lecture Prize Recipient for her groundbreaking discovery of CBF-beta, RUNX1 hematopoeisis, and ongoing research in RUNX1-FPD. @ASH_hematology #ASH25

[Mohamad Mohty @Mohty_EBMT]

Very proud to see our ARES study, demonstrating for the 1st time the efficacy of a fecal microbiota product in severe acute GVHD, featured in #ASH25 Newsdaily. More than a decade of rigorous research has now translated into a truly remarkable milestone. ⁦@MaaT_Pharma⁩

[GvHD Hub @gvhd_hub]

CONGRESS | #ASH25 | PRESENTATION

Amandeep Salhotra shares results of a phase I trial of allogeneic CD6-CAR Tregs in patients with steroid-dependent or steroid-refractory #cGvHD (N = 6), noting that they can be successfully manufactured and cryopreserved. CD6-CAR Tregs cell infusion was not associated with significant toxicity, including CRS, ICANS, or GvHD flare.

Follow our live feed for more updates: https://t.co/oAmzxmLxXa

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress @cityofhope

[Supriya Gupta, MD @SupriyaGuptaMD]

ICYMI: My piece covering Prof. Chiara Bonini’s inspiring Ham-Wasserman lecture was featured in today’s #ASHNewsDaily

Prof. Bonini took us through a journey in gene editing, innovation and the rapidly evolving future of cancer immunotherapy. 🧬

Grab your copy today!

#ASH25

[Saurabh Zanwar @ZanwarSaurabh]

Check out this #ASH25 special interest session on clonal hematopoesis today.

To all the GoT fans out there, here is our take covering the session highlights in today’s ASH Daily news!

@EmperorBlackMD @JoselleCookMD @ASH_hematology @CKBrierley @majorajay @ChrisGrahamMD @SupriyaGuptaMD

https://t.co/iNOJXFVR6r

[Christopher Graham @ChrisGrahamMD]

Great plenary session from Irenaeus Chan of the Bolton lab who presented their findings of trilaciclib, a CDK4/6 inhibitor, and its impact on reducing TP53 mutated hematopoeisis following chemotherapy. #ASH25 @ASH_hematology @KellyLBolton

[Dr. Uma Borate: Associate Professor @beatalleukemia]

#ASHkudos to plenary from @KellyLBolton lab & collaborated @AbdelWahablab tackling THE most important clinical issue for our patients- potential prevention of t-MN by suppressing TP53 clonal expansion. A topic close to my heart. Onwards ! #ASH25

[Esra Gülderen @gulderenesra]

🧵#ASH25 Highlights in transplant & cellular therapy
A new era where both fields are rapidly converging into precision-engineered, potentially broader curative platforms. Here are the standout my fav advances👇
@ASH_hematology

[Amisha Gupta @amishagupta2012]

Great presentation by my colleague @SupriyaGuptaMD at #ASH25 👏

Allo CD19 CAR T azer-cel + low-dose SC IL-2 for LBCL relapsing after auto CAR T (n=12)
• ORR 75%, CR 50%
• CRS 67% (Gr 1–2), ICANS 17% (Gr 2–3), infections 33% (all Gr 2)

@ASHClinicalNews @ASH_hematology

[Lymphoma Hub @lymphomahub]

CONGRESS | #ASH25 | PRESENTATION
Supriya Gupta presents findings from a phase I/Ib trial of azer-cel, an allogeneic CD19 CAR T-cell therapy + low-dose interleukin-2 (IL-2) in patients with LBCL who relapsed after autologous CAR T-cell therapy (N = 18).

Azer-cel + low-dose IL-2 showed a manageable safety profile with Grade 1–2 CRS reported in 72.2% of patients and Grade 1–3 ICANS in 16.7% of all patients. Among the efficacy set (n = 16), the ORR was 81.0% with a CR rate of 43.8%. Robust CAR T-cell expansion was observed among responders (n = 13).

Follow our live feed for more updates: https://t.co/QvRGEzhpSL
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @SupriyaGuptaMD @UMNHOT @UMNCancer

[Christopher Graham @ChrisGrahamMD]

High early responses following Azer-cel in heavily pretreated, prior CD19 CAR-T relapse with ORR 81%, CR 44%. Can allo CAR-Ts with IL2 be an answer to T cell exhaustion and post CAR relapse? #ASH25 @SupriyaGuptaMD @TeamImugene

[Supriya Gupta, MD @SupriyaGuptaMD]

Join Prof. Chiara Bonini at the Ham Wasserman lecture today from 12:30 to 1:30 pm in West Hall D2 for an exciting presentation on how gene editing is reshaping cellular immunotherapy. #ASH25 #ASHNewsDaily @ASH_hematology

[Christopher Graham @ChrisGrahamMD]

See the most recent update in alloCAR-19 for patients DLBCL relapsed after standard CAR-19 therapy, with an impressive ORR in this heavily pretreated patient population @ASH_hematology #lymsm #ASH25

[Supriya Gupta, MD @SupriyaGuptaMD]

Excited to present our oral abstract at #ASH25 on the safety and efficacy of Azer-cel in LBCL in post-CAR-T relapse setting. Join me at 2:30 pm in West Hall D2. @TeamImugene

[Supriya Gupta, MD @SupriyaGuptaMD]

Excited to present our oral abstract at #ASH25 on the safety and efficacy of Azer-cel in LBCL in post-CAR-T relapse setting. Join me at 2:30 pm in West Hall D2. @TeamImugene